1276056-83-7 Usage
Description
(4-bromo-1-methyl-1H-pyrazol-5-yl)methanol, a chemical compound with the molecular formula C6H7BrN2O, is a white to off-white solid. It is widely recognized in the fields of medicinal chemistry and pharmaceuticals for its role as a fundamental building block in the synthesis of an array of pharmaceuticals and agrochemicals. This versatile compound has garnered attention for its potential applications in therapeutic development, making it a valuable asset in the chemical and healthcare industries.
Uses
Used in Pharmaceutical Industry:
(4-bromo-1-methyl-1H-pyrazol-5-yl)methanol is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique molecular structure allows it to be a crucial component in the development of novel drug candidates designed to treat a wide range of diseases. (4-broMo-1-Methyl-1H-pyrazol-5-yl)Methanol's versatility in chemical reactions makes it an indispensable tool in the creation of new and innovative medications.
Used in Agrochemical Industry:
In the agrochemical sector, (4-bromo-1-methyl-1H-pyrazol-5-yl)methanol serves as a vital building block for the synthesis of different agrochemicals. Its incorporation into these products aids in enhancing crop protection, yield, and overall agricultural productivity. (4-broMo-1-Methyl-1H-pyrazol-5-yl)Methanol's stability and reactivity contribute to its effectiveness in developing new agrochemical solutions to combat pests and diseases in the agricultural domain.
Overall, (4-bromo-1-methyl-1H-pyrazol-5-yl)methanol is a multifaceted chemical compound with significant applications across the pharmaceutical and agrochemical industries. Its role in the synthesis of various products and its potential for therapeutic applications make it a valuable resource for researchers and developers alike.
Check Digit Verification of cas no
The CAS Registry Mumber 1276056-83-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,7,6,0,5 and 6 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1276056-83:
(9*1)+(8*2)+(7*7)+(6*6)+(5*0)+(4*5)+(3*6)+(2*8)+(1*3)=167
167 % 10 = 7
So 1276056-83-7 is a valid CAS Registry Number.
1276056-83-7Relevant articles and documents
MACROCYCLES AND THEIR USE
-
Paragraph 0718-0720, (2022/02/06)
The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.
Lysophosphatidic acid receptor antagonists and preparation method thereof
-
, (2020/07/29)
The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.
SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
-
Paragraph 0261, (2019/10/15)
The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
